Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

History

SNBL began in 1959 as the Shin Nippon Kyodo Unso Co. Ltd. (SNKU). In 1966, it was renamed Shin Nippon Biomedical Laboratories, Ltd. Over the years, it has earned a reputation as a world-class service provider and has become one of the leading CROs in Japan. It has also become a trusted partner for many leading international companies in the pharmaceutical, biotechnology and medical device industries.

Mission

We strive to provide world-class clinical research services, ensuring superior quality and regulatory compliance to meet and exceed customer needs.

Vision

We aim to be the leading provider of clinical research services in Japan, and a powerhouse of contract research in the global CRO industry.

Key Team

Shinji Nitanda (Sr. MD of Corp. Devel. and Corp. Fin. & Director)

Kyomi Nagatoshi (Sr. Exec. Officer and GM of Gen. Affairs & Personnel Division)

Mr. Ken Takanashi CPA, CPA, M.B.A., MBA. (VP of Group Company Collaboration Supervision and Global business Mgt & Representative Director)

Satoshi Matsumoto (Managing Exec. Officer & Sustainable Devel. Company Pres of Fisheries Division)

Terumasa Hirai (Managing Exec. Officer)

Mr. Ichiro Nagata (MD & Director)

Takashi Iriyama (Managing Exec. Officer & GM of Corp. Strategy Headquarters)

Recognition and Awards

The company has been recognized with several awards, including the Good Clinical Practice Award, Quality Management Titanium Award and numerous other awards from various national and international organizations.

References

https://in.investing.com/equities/shin-nippon-biomed-lab-company-profile

https://finance.yahoo.com/quote/2395.T/profile?p=2395.T

https://www.crunchbase.com/organization/shin-nippon-biomedical-laboratories

https://www.snbl.co.jp

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D. (Chairman, Global CEO, Pres & CHO)

Fumihiko Makino (Sr. Exec. Officer, Financial Controller and GM of Fin. & Accounting)

Toshiyuki Iwata (Managing Exec. Officer and GM of IR PR Department & Special Mission)

Products/ Services

Biotechnology, Pharmaceutical

Number of Employees

1,000 - 20,000

Headquarters

Tokyo, Tokyo, Japan

Established

1957

Net Income

20M - 100M

Revenue

100M - 500M

Traded as

TYO:2395

Social Media

URL

https://www.snbl.co.jp

Last updated: Tue Feb 25 2025

We value your privacy

Shin Nippon Biomedical Laboratories (SNBL)

Table of content

Summary